Skip to content

Study · In vitro (cells) · 2009

8 results

Thymulin and zinc (Zn2+)-mediated inhibition of endotoxin-induced production of proinflammatory cytokines and NF-kappaB nuclear translocation and activation in the alveolar epithelium: unraveling the molecular immunomodulatory, anti-inflammatory effect of thymulin/Zn2+ in vitro.

Haddad JJ

Molecular immunology21 Oct 2009Cited by 21 (Europe PMC)

PMID19850345 (opens in a new tab)DOI10.1016/j.molimm.2009.09.034 (opens in a new tab)PepBankPUB-19850345
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin dose-dependently reduced endotoxin-induced IL-1beta release.

    In plain wordsIn cells, thymulin reduced endotoxin-induced IL-1beta release as the dose increased.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseIL-1beta release
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymulin selectively ameliorated, in a dose-dependent manner, the endotoxin (ET/LPS [lipopolysaccharide])-induced release of IL-1beta, but not IL-6 or TNF-alpha.
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.
  2. 02LabIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin did not reduce endotoxin-induced IL-6 release.

    In plain wordsIn cells, thymulin did not reduce endotoxin-induced IL-6 release.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeIL-6 release
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymulin selectively ameliorated, in a dose-dependent manner, the endotoxin (ET/LPS [lipopolysaccharide])-induced release of IL-1beta, but not IL-6 or TNF-alpha.
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.
  3. 03LabIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin did not reduce endotoxin-induced TNF-alpha release.

    In plain wordsIn cells, thymulin did not reduce endotoxin-induced TNF-alpha release.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    No significant changeTNF-alpha release
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Thymulin selectively ameliorated, in a dose-dependent manner, the endotoxin (ET/LPS [lipopolysaccharide])-induced release of IL-1beta, but not IL-6 or TNF-alpha.
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.
  4. 04LabIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin increased cAMP release in a dose- and time-dependent manner.

    In plain wordsIn cells, thymulin increased cAMP release depending on dose and exposure time.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    IncreasecAMP release
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, thymulin upregulated, in a dose- and time-dependent manner, the release of the nucleotide cAMP.
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.
  5. 05LabIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin reduced RelA nuclear translocation.

    In plain wordsIn cells, thymulin reduced movement of RelA into the nucleus.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseRelA nuclear translocation
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Alveolar epithelial cells treated with thymulin markedly showed a downregulation of the nuclear translocation of RelA (p65), the major transactivating member of the NF-kappaB family, in addition to NF-kappaB(1) (p50) and c-Rel (p75), an effect mildly substantiated with Zn(2+).
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.
  6. 06LabIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin reduced NF-kappaB(1) nuclear translocation.

    In plain wordsIn cells, thymulin reduced movement of p50 into the nucleus.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Decreasep50 nuclear translocation
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Alveolar epithelial cells treated with thymulin markedly showed a downregulation of the nuclear translocation of RelA (p65), the major transactivating member of the NF-kappaB family, in addition to NF-kappaB(1) (p50) and c-Rel (p75), an effect mildly substantiated with Zn(2+).
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.
  7. 07LabIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin reduced c-Rel nuclear translocation.

    In plain wordsIn cells, thymulin reduced movement of c-Rel into the nucleus.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    Decreasec-Rel nuclear translocation
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Alveolar epithelial cells treated with thymulin markedly showed a downregulation of the nuclear translocation of RelA (p65), the major transactivating member of the NF-kappaB family, in addition to NF-kappaB(1) (p50) and c-Rel (p75), an effect mildly substantiated with Zn(2+).
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.

Studies that did not test the peptide alone1

In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymulin (serum thymic factor).

  1. 08LabNot a test of Thymulin (serum thymic factor) aloneIn vitro (cells)Mechanism

    In fetal alveolar epithelial cells, thymulin with zinc dose-dependently reduced NF-kappaB DNA-binding activity.

    In plain wordsIn cells, thymulin with zinc reduced NF-kappaB binding to DNA as the dose increased.

    Peptide
    Thymulin (serum thymic factor)
    Outcome
    DecreaseNF-kappaB DNA binding
    Study

    n: not reported in source

    Fetal alveolar type II epithelial cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation

    Source sentences

    Summary
    Furthermore, thymulin/Zn(2+) reduced, in a dose-dependent manner, the DNA-binding activity of NF-kappaB (RelA/p65).
    1 context sentence
    Summary · context
    In an in vitro model of fetal alveolar type II epithelial cells (FATEII), we have investigated the exhibition of an anti-inflammatory activity of this peptide hormone.

    In this study, Thymulin (serum thymic factor) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymulin (serum thymic factor).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:55 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.